ASCO 2021: Rituximab Plus Copanlisib Shows Benefit in Relapsed Follicular and Marginal Zone Lymphoma
Pre-specified subset analysis of CHRONOS-3 confirms benefits of the combination in this patient population
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.